Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant Osteosarcoma and Ewing's family tumor cells

Yan Li, Kazuhiro Tanaka, Xu Li, Takamitsu Okada, Tomoyuki Nakamura, Minoru Takasaki, Shunsaku Yamamoto, Yoshinao Oda, Masazumi Tsuneyoshi, Yukihide Iwamoto

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Multimodal therapies play important roles in the treatment of osteosarcoma (OS) and Ewing's family of tumors (EFTs), two most frequent malignant bone tumors. Although the clinical outcome of primary OS and EFTs is greatly improved, the relapsed cases often are associated with multidrug resistance of the tumors and the prognosis of these patients is still poor. Flavopiridol, a pan cyclin-dependent kinase (CDK) inhibitor is a novel antitumor agent that can induce cell cycle arrest and apoptosis in many cancer cells. However, there have been no studies about the effects of flavopiridol on drug-resistant OS and EFTs. Here, we demonstrated that flavopiridol induced the cleavage of poly-ADP-ribose polymerase (PARP) in a time and dose dependent manner in adriamycin-resistant OS and EFTs cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) as effectively as in their parental cells. Our data also snowed that flavopiridol caused the release of mitochondrial cytochrome c and the activation of caspase-9, caspase-8 and caspase-3, with an increase ratio of the proapoptotic protein level (Bax) to the antiapoptotic protein level (Bcl-2 and Bcl-XL), while apoptosis was inhibited by pan caspase inhibitor (Z-VAD-FMK) and caspase-3 inhibitor (Z-DEVD-FMK), not by caspase-8 inhibitor (Z-IETD-FMK). The treatment with flavopiridol further inhibited the tumor growth in mouse models of the drug-resistant OS and EFTs. These results suggest that flavopiridol might be promising in clinical therapy for the relapsed OS and EFTs.

Original languageEnglish
Pages (from-to)1212-1218
Number of pages7
JournalInternational Journal of Cancer
Volume121
Issue number6
DOIs
Publication statusPublished - Sep 15 2007

Fingerprint

alvocidib
Ewing's Sarcoma
Cyclin-Dependent Kinases
Osteosarcoma
Apoptosis
Caspase Inhibitors
Growth
Pharmaceutical Preparations
Neoplasms
Caspase 8
Caspase 3
Play Therapy
bcl-2-Associated X Protein
Poly(ADP-ribose) Polymerases
Caspase 9
Multiple Drug Resistance
P-Glycoprotein
Cell Cycle Checkpoints
Cytochromes c
Antineoplastic Agents

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant Osteosarcoma and Ewing's family tumor cells. / Li, Yan; Tanaka, Kazuhiro; Li, Xu; Okada, Takamitsu; Nakamura, Tomoyuki; Takasaki, Minoru; Yamamoto, Shunsaku; Oda, Yoshinao; Tsuneyoshi, Masazumi; Iwamoto, Yukihide.

In: International Journal of Cancer, Vol. 121, No. 6, 15.09.2007, p. 1212-1218.

Research output: Contribution to journalArticle

Li, Yan ; Tanaka, Kazuhiro ; Li, Xu ; Okada, Takamitsu ; Nakamura, Tomoyuki ; Takasaki, Minoru ; Yamamoto, Shunsaku ; Oda, Yoshinao ; Tsuneyoshi, Masazumi ; Iwamoto, Yukihide. / Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant Osteosarcoma and Ewing's family tumor cells. In: International Journal of Cancer. 2007 ; Vol. 121, No. 6. pp. 1212-1218.
@article{196e7d0d7f674f0d80bbc5ce457f1d1a,
title = "Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant Osteosarcoma and Ewing's family tumor cells",
abstract = "Multimodal therapies play important roles in the treatment of osteosarcoma (OS) and Ewing's family of tumors (EFTs), two most frequent malignant bone tumors. Although the clinical outcome of primary OS and EFTs is greatly improved, the relapsed cases often are associated with multidrug resistance of the tumors and the prognosis of these patients is still poor. Flavopiridol, a pan cyclin-dependent kinase (CDK) inhibitor is a novel antitumor agent that can induce cell cycle arrest and apoptosis in many cancer cells. However, there have been no studies about the effects of flavopiridol on drug-resistant OS and EFTs. Here, we demonstrated that flavopiridol induced the cleavage of poly-ADP-ribose polymerase (PARP) in a time and dose dependent manner in adriamycin-resistant OS and EFTs cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) as effectively as in their parental cells. Our data also snowed that flavopiridol caused the release of mitochondrial cytochrome c and the activation of caspase-9, caspase-8 and caspase-3, with an increase ratio of the proapoptotic protein level (Bax) to the antiapoptotic protein level (Bcl-2 and Bcl-XL), while apoptosis was inhibited by pan caspase inhibitor (Z-VAD-FMK) and caspase-3 inhibitor (Z-DEVD-FMK), not by caspase-8 inhibitor (Z-IETD-FMK). The treatment with flavopiridol further inhibited the tumor growth in mouse models of the drug-resistant OS and EFTs. These results suggest that flavopiridol might be promising in clinical therapy for the relapsed OS and EFTs.",
author = "Yan Li and Kazuhiro Tanaka and Xu Li and Takamitsu Okada and Tomoyuki Nakamura and Minoru Takasaki and Shunsaku Yamamoto and Yoshinao Oda and Masazumi Tsuneyoshi and Yukihide Iwamoto",
year = "2007",
month = "9",
day = "15",
doi = "10.1002/ijc.22820",
language = "English",
volume = "121",
pages = "1212--1218",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant Osteosarcoma and Ewing's family tumor cells

AU - Li, Yan

AU - Tanaka, Kazuhiro

AU - Li, Xu

AU - Okada, Takamitsu

AU - Nakamura, Tomoyuki

AU - Takasaki, Minoru

AU - Yamamoto, Shunsaku

AU - Oda, Yoshinao

AU - Tsuneyoshi, Masazumi

AU - Iwamoto, Yukihide

PY - 2007/9/15

Y1 - 2007/9/15

N2 - Multimodal therapies play important roles in the treatment of osteosarcoma (OS) and Ewing's family of tumors (EFTs), two most frequent malignant bone tumors. Although the clinical outcome of primary OS and EFTs is greatly improved, the relapsed cases often are associated with multidrug resistance of the tumors and the prognosis of these patients is still poor. Flavopiridol, a pan cyclin-dependent kinase (CDK) inhibitor is a novel antitumor agent that can induce cell cycle arrest and apoptosis in many cancer cells. However, there have been no studies about the effects of flavopiridol on drug-resistant OS and EFTs. Here, we demonstrated that flavopiridol induced the cleavage of poly-ADP-ribose polymerase (PARP) in a time and dose dependent manner in adriamycin-resistant OS and EFTs cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) as effectively as in their parental cells. Our data also snowed that flavopiridol caused the release of mitochondrial cytochrome c and the activation of caspase-9, caspase-8 and caspase-3, with an increase ratio of the proapoptotic protein level (Bax) to the antiapoptotic protein level (Bcl-2 and Bcl-XL), while apoptosis was inhibited by pan caspase inhibitor (Z-VAD-FMK) and caspase-3 inhibitor (Z-DEVD-FMK), not by caspase-8 inhibitor (Z-IETD-FMK). The treatment with flavopiridol further inhibited the tumor growth in mouse models of the drug-resistant OS and EFTs. These results suggest that flavopiridol might be promising in clinical therapy for the relapsed OS and EFTs.

AB - Multimodal therapies play important roles in the treatment of osteosarcoma (OS) and Ewing's family of tumors (EFTs), two most frequent malignant bone tumors. Although the clinical outcome of primary OS and EFTs is greatly improved, the relapsed cases often are associated with multidrug resistance of the tumors and the prognosis of these patients is still poor. Flavopiridol, a pan cyclin-dependent kinase (CDK) inhibitor is a novel antitumor agent that can induce cell cycle arrest and apoptosis in many cancer cells. However, there have been no studies about the effects of flavopiridol on drug-resistant OS and EFTs. Here, we demonstrated that flavopiridol induced the cleavage of poly-ADP-ribose polymerase (PARP) in a time and dose dependent manner in adriamycin-resistant OS and EFTs cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) as effectively as in their parental cells. Our data also snowed that flavopiridol caused the release of mitochondrial cytochrome c and the activation of caspase-9, caspase-8 and caspase-3, with an increase ratio of the proapoptotic protein level (Bax) to the antiapoptotic protein level (Bcl-2 and Bcl-XL), while apoptosis was inhibited by pan caspase inhibitor (Z-VAD-FMK) and caspase-3 inhibitor (Z-DEVD-FMK), not by caspase-8 inhibitor (Z-IETD-FMK). The treatment with flavopiridol further inhibited the tumor growth in mouse models of the drug-resistant OS and EFTs. These results suggest that flavopiridol might be promising in clinical therapy for the relapsed OS and EFTs.

UR - http://www.scopus.com/inward/record.url?scp=34548081194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548081194&partnerID=8YFLogxK

U2 - 10.1002/ijc.22820

DO - 10.1002/ijc.22820

M3 - Article

C2 - 17520676

AN - SCOPUS:34548081194

VL - 121

SP - 1212

EP - 1218

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -